Peptide Market Hits $140 Billion—But a Hidden Quality Crisis Threatens Drug Innovation

New York, Wednesday, 17 June 2026.
A new report reveals the peptide therapeutics market is booming at $140 billion, yet a dangerous divide in quality standards between FDA-approved drugs and research-grade peptides could stall breakthroughs. With over 600 peptide candidates in preclinical development, inconsistent purity in research supplies risks delaying critical drug discoveries—putting billions in investments and patient treatments on the line.